Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).

Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A, Sabin C; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort (CHIC) Study.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):633-9.


Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay.

Ellis GM, Page LC, Burman BE, Buskin S, Frenkel LM.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):283-9. doi: 10.1097/QAI.0b013e3181a9972c.


Adherence to antiretrovirals among US women during and after pregnancy.

Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, Stek A, Buschur S, Cotter A, Bettica L, Read JS; PACTG 1025 Protocol Team.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):408-17. doi: 10.1097/QAI.0b013e31817bbe80.


Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.

Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, Higgins A, Zorrilla C, Landesman S, Serchuck L, Larussa P.

AIDS Care. 2008 Sep;20(8):958-68. doi: 10.1080/09540120701767208.


Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.


Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team.

HIV Clin Trials. 2008 Mar-Apr;9(2):115-25. doi: 10.1310/hct0902-115.


The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD.

AIDS. 2007 Oct 1;21(15):2033-42.


Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.


Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jiménez E, McSherry G, Mofenson L.

Antimicrob Agents Chemother. 2007 Jun;51(6):2208-10. Epub 2007 Apr 9.


Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.

Unadkat JD, Wara DW, Hughes MD, Mathias AA, Holland DT, Paul ME, Connor J, Huang S, Nguyen BY, Watts DH, Mofenson LM, Smith E, Deutsch P, Kaiser KA, Tuomala RE.

Antimicrob Agents Chemother. 2007 Feb;51(2):783-6. Epub 2006 Dec 11.


Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.

Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):301-6.


Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S, Naugler WE, Pawluk DM, Li CC, Frenkel LM.

J Clin Microbiol. 2004 Aug;42(8):3670-4.


Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels.

Ahdieh Grant L, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, Nowicki M, Kovacs A, Cohen M, Muñoz A.

AIDS. 2001 Nov 9;15(16):2101-8.


HIV-infected pregnant women and progression of HIV disease.

Buskin SE, Diamond C, Hopkins SG.

Arch Intern Med. 1998 Jun 8;158(11):1277-8. No abstract available.


Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group.

Alliegro MB, Dorrucci M, Phillips AN, Pezzotti P, Boros S, Zaccarelli M, Pristerà R, Rezza G.

Arch Intern Med. 1997 Dec 8-22;157(22):2585-90.


The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load.

Burns DN, Landesman S, Minkoff H, Wright DJ, Waters D, Mitchell RM, Rubinstein A, Willoughby A, Goedert JJ.

Am J Obstet Gynecol. 1998 Feb;178(2):355-9.


Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant.

Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C, Song JL, Jin Z, Zhao JQ, Clapp S, Chen IS, Ho DD, Ammann AJ.

Nat Med. 1997 May;3(5):549-52.


Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women.

Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, King PD, Johnson EJ, Williams BL, Frenkel LM, Coombs RW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):232-6.


Maternal human immunodeficiency virus-1 infection and pregnancy outcome.

Temmerman M, Chomba EN, Ndinya-Achola J, Plummer FA, Coppens M, Piot P.

Obstet Gynecol. 1994 Apr;83(4):495-501.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk